Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan J Korman

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Plos One|June 8, 2018
An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patientsElizabeth Colston, Dennis Grasela, David Gardiner, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 7, 2010
Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapySara M Mangsbo, Linda C Sandin, Kerstin Anger, et al.
Cancer Cell|June 7, 2016
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR EngagementRony Dahan, Bryan C Barnhart, Fubin Li, et al.
Nature Reviews. Cancer|July 25, 2015
Evolving synergistic combinations of targeted immunotherapies to combat cancerIgnacio Melero, David M Berman, M Angela Aznar, et al.
Cancer Immunology Research|April 30, 2014
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cellsMark J Selby, John J Engelhardt, Michael Quigley, et al.
International Immunology|September 28, 2007
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLsRaymond M Wong, Ron R Scotland, Roy L Lau, et al.
Cellular Immunology|November 7, 2017
Conditioned media from the renal cell carcinoma cell line 786.O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotypeShannon L Okada, Randi M Simmons, Secil Franke-Welch, et al.
Cancer Immunology Research|November 28, 2019
Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV<sup>+</sup> CancersGabriele Galliverti, Stephan Wullschleger, Mélanie Tichet, et al.
Cancer Immunology Research|August 18, 2022
Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with NivolumabKent Thudium, Mark Selby, Julie A Zorn, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 5, 2012
In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized miceBrent E Palmer, C Preston Neff, Jonathan Lecureux, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Plos One|June 8, 2018
An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patientsElizabeth Colston, Dennis Grasela, David Gardiner, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 7, 2010
Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapySara M Mangsbo, Linda C Sandin, Kerstin Anger, et al.
Cancer Cell|June 7, 2016
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR EngagementRony Dahan, Bryan C Barnhart, Fubin Li, et al.
Nature Reviews. Cancer|July 25, 2015
Evolving synergistic combinations of targeted immunotherapies to combat cancerIgnacio Melero, David M Berman, M Angela Aznar, et al.
Cancer Immunology Research|April 30, 2014
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cellsMark J Selby, John J Engelhardt, Michael Quigley, et al.
International Immunology|September 28, 2007
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLsRaymond M Wong, Ron R Scotland, Roy L Lau, et al.
Cellular Immunology|November 7, 2017
Conditioned media from the renal cell carcinoma cell line 786.O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotypeShannon L Okada, Randi M Simmons, Secil Franke-Welch, et al.
Cancer Immunology Research|November 28, 2019
Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV<sup>+</sup> CancersGabriele Galliverti, Stephan Wullschleger, Mélanie Tichet, et al.
Cancer Immunology Research|August 18, 2022
Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with NivolumabKent Thudium, Mark Selby, Julie A Zorn, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 5, 2012
In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized miceBrent E Palmer, C Preston Neff, Jonathan Lecureux, et al.
Pageof 7